Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8+ T cell fate.

Research square·2026

Same author

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.

Science advances·2026

Same author

Volumetric Ultrasound Imaging Based on 4096-Element Large-Aperture 2D Array.

IEEE transactions on ultrasonics·2026

Same author

A wearable non-invasive sonogenetic pacemaker.

Nature biomedical engineering·2026

Same author

Ultrasound phase microscopy for rapid label-free super-resolution vascular imaging.

Research square·2026

Same author

Prospect of Wearable Ultrasound.

BME frontiers·2026

Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026

Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026

Same journal

Structural basis for host membrane binding and remodeling by invading malaria parasites.

Cell·2026

Same journal

Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning.

Cell·2026

Same journal

Arc mediates intercellular tau transmission via extracellular vesicles.

Cell·2026

Same journal

Electromagnetic field-inducible in vivo gene switch for remote spatiotemporal control of gene expression.

Cell·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 14, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Engineering sonogenetic EchoBack-CAR T cells.

Longwei Liu¹, Peixiang He², Yuxuan Wang¹

¹Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.

|April 3, 2025

Summary

This summary is machine-generated.

Sonogenetic EchoBack-CAR T cells offer a novel approach to solid tumor treatment. These engineered cells provide long-lasting expression and potent anti-tumor activity with reduced toxicity, enhancing therapeutic potential.

Keywords:

CAR T feedback engineering immunotherapy inducible gene expression promoter library screening solid tumor sonogenetics spatiotemporal CAR regulation ultrasound controled CAR-T

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Apr 14, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Area of Science:

Immunology
Biotechnology
Oncology

Background:

Chimeric antigen receptor (CAR) T cell therapy faces challenges in solid tumors, including toxicity, T cell exhaustion, and limited persistence.
Targeting solid tumors requires innovative strategies to overcome these limitations and improve therapeutic efficacy.

Purpose of the Study:

To engineer sonogenetic EchoBack-CAR T cells for controlled and sustained CAR expression upon focused ultrasound (FUS) stimulation.
To evaluate the efficacy and safety of EchoBack-CAR T cells in preclinical models of glioblastoma and prostate cancer.

Main Methods:

Screening of an ultrasensitive heat-shock promoter library for integration into CAR T cells.
Engineering a positive feedback loop for sustained CAR expression triggered by FUS.
Preclinical evaluation in 3D glioblastoma models and in vivo mouse models for glioblastoma and prostate cancer.

Main Results:

EchoBack-CAR T cells demonstrated potent cytotoxicity and enhanced persistence in glioblastoma models.
In vivo studies showed effective glioblastoma suppression by EchoBack-hGD2CAR T cells without off-tumor toxicity.
Single-cell RNA sequencing indicated improved cytotoxicity and reduced exhaustion in EchoBack-CAR T cells.
The EchoBack-PSMACAR T cell strategy showed long-lasting prostate cancer suppression with minimal off-tumor toxicity.

Conclusions:

Sonogenetic EchoBack-CAR T cells represent a versatile, efficient, and safe platform for solid tumor treatment.
The FUS-inducible system allows for controlled CAR T cell activity, mitigating on-target off-tumor toxicities.
This technology holds promise for improving CAR T cell therapy outcomes in various solid malignancies.